single30MG
PNC-27
30MG Protocol
PNC-27 30MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
3.0 mL BAC water
Selective cytotoxicity toward HDM-2 surface-expressing cancer cells in preclinical studies
Direct membrane-destabilization/lysis mechanism described rather than apoptosis
Tumor-growth inhibition signals in animal models
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 100 mcg (0.10 mg) | 1 |
| 2 | Weeks 3–4 | 200 mcg (0.20 mg) | 2 |
| 3 | Weeks 5–8 | 300 mcg (0.30 mg) | 3 |
| 4 | Weeks 9–12 | 400 mcg (0.40 mg) | 4 |
| 5 | Weeks 13–16 | 500 mcg (0.50 mg) | 5 |
Inject once daily
8–12 weeks; optional extension to 16 weeks
PNC-27 is described as an experimental chimeric peptide built from a segment of the p53 tumor suppressor protein fused to a membrane-penetrating leader sequence. The protocol’s mechanism section centers on selectivity for cancer cells: PNC-27 is described as binding HDM-2 (MDM2) when HDM-2 is expressed on the surface of malignant cells. This interaction is presented as destabilizing the cancer-cell membrane and causing necrotic cell death, while largely sparing normal cells that do not display the same surface HDM-2 pattern. The page emphasizes that this is not classic apoptosis signaling but more akin to direct membrane lysis at the malignant cell surface. Preclinical mouse tumor-model findings are cited as showing inhibition of tumor growth with intraperitoneal administration. The protocol repeatedly notes that no human clinical studies exist and that dosing and safety in humans remain theoretical extrapolations from early laboratory research.
No established human safety/efficacy data (explicitly noted)
Possible injection-site reactions (redness/irritation)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)